ResultsIQ

ResultsIQ › Latest results › Shilpa Medicare Limited

Shilpa Medicare Limited Q4 FY25 earnings call summary

NSE: SHILPAMED · BSE: 530549

Earnings call of 26 May 2025, summarised by AI from the filing.

Formulation growth from Nilotinib and RoW tenders; Biologics from Adalimumab doubling; API from new products.

Key takeaways

  1. Growth drivers Formulation growth from Nilotinib and RoW tenders; Biologics from Adalimumab doubling; API from new products.
  2. Risk USFDA import alert on formulation facility; remediation done, awaiting response.

Original filing on BSE

Shilpa Medicare Limited Q1 FY27 results

As filed: Revenue ₹466 cr (+45% year on year), EBITDA ₹136 cr (+48% year on year), PAT ₹101 cr (+115% year on year), EBITDA margin 29.3% (+59 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹437 cr (+32% year on year), EBITDA ₹120 cr (+58% year on year), PAT ₹108 cr (+88% year on year), EBITDA margin 27.4% (+443 bps). Score 76 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit before exceptional items growth was below it. EBITDA margin rose 443 bps year on year. Tax rate 11%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Profit before exceptional items rose ₹36.1 cr on a year ago, more than the ₹19.0 cr it added the year before. Share price after the results: +16.2% in 28 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹410 cr (+28% year on year), EBITDA ₹114 cr (+41% year on year), PAT ₹44.6 cr (+81% year on year), EBITDA margin 27.9% (+250 bps). Score 81 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit before exceptional items growth was below it. EBITDA margin rose 250 bps year on year. Consolidated profit +39% but standalone 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit before exceptional items rose ₹33.1 cr on a year ago, more than the ₹26.0 cr it added the year before. Share price after the results: +5.4% in 28 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹370 cr (+8% year on year), EBITDA ₹109 cr (+27% year on year), PAT ₹44.0 cr (+144% year on year), EBITDA margin 29.5% (+446 bps). Score 49 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 446 bps year on year. Profit fell 6% from last quarter. Profit rose ₹26.0 cr on a year ago, more than the ₹16.0 cr it added the year before. Share price after the results: −17.2% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹321 cr (+10% year on year), EBITDA ₹92.0 cr (+24% year on year), PAT ₹47.0 cr (+236% year on year), EBITDA margin 28.7% (+340 bps). Score 42 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 340 bps year on year. Tax rate 6%. Consolidated profit +236% but standalone -25%. Revenue fell 3% from last quarter. Revenue rose ₹28.0 cr on a year ago, against ₹33.0 cr the year before. Share price after the results: −8.7% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹331 cr (+13% year on year), EBITDA ₹76.0 cr (+7% year on year), PAT ₹15.0 cr (+86% year on year), EBITDA margin 23.0% (−135 bps). Score 27 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was well below it. EBITDA margin fell 135 bps year on year. Other income 62% of PBT. Tax rate 8%. Revenue rose ₹39.0 cr on a year ago, more than the ₹28.0 cr it added the year before. Share price after the results: −3.7% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹319 cr (+12% year on year), EBITDA ₹81.0 cr (+23% year on year), PAT ₹32.0 cr (+300% year on year), EBITDA margin 25.4% (+231 bps). Score 35 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was well below it. EBITDA margin rose 231 bps year on year. Revenue fell 7% from last quarter.
  • Q2 FY25: Revenue ₹344 cr (+10% year on year), EBITDA ₹86.0 cr (+43% year on year), PAT ₹18.0 cr (+300% year on year), EBITDA margin 25.0% (+583 bps). Score 75 of 100, Above trend. EBITDA margin rose 583 bps year on year. Tax rate 51%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Shilpa Medicare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.